In the pursuit of faster and more reliable recombinant protein production, transient transfection has emerged as a cornerstone of early biopharmaceutical development. Compared to stable transfection, ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development ...

Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...